tacrine has been researched along with Disease Exacerbation in 7 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this retrospective analysis of 443 Alzheimer disease (AD) patients from a 30-week tacrine trial, change in Alzheimer's Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/APOE genotype interaction." | 5.11 | Cholesterol and APOE genotype interact to influence Alzheimer disease progression. ( Evans, RM; Farlow, MR; Hui, S; Lahiri, DK; Perkins, A; Poirier, J, 2004) |
| " Dosing was initiated at 40 mg/day and increased in increments of 40 mg/day every 6 weeks until the target dose was achieved." | 2.68 | Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients. ( Smith, F, 1996) |
| "Tacrine dosages have been studied in 5 protocols that used either enrichment or parallel designs." | 2.39 | The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. ( Holford, NH; Peace, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atri, A | 1 |
| Evans, RM | 1 |
| Hui, S | 1 |
| Perkins, A | 1 |
| Lahiri, DK | 1 |
| Poirier, J | 1 |
| Farlow, MR | 1 |
| Holford, NH | 1 |
| Peace, K | 1 |
| Marx, J | 1 |
| Smith, F | 1 |
| Sjögren, M | 1 |
| Hesse, C | 1 |
| Basun, H | 1 |
| Köl, G | 1 |
| Thostrup, H | 1 |
| Kilander, L | 1 |
| Marcusson, J | 1 |
| Edman, A | 1 |
| Wallin, A | 1 |
| Karlsson, I | 1 |
| Troell, M | 1 |
| Wachtmaister, G | 1 |
| Ekdahl, A | 1 |
| Olofsson, H | 1 |
| Sandström, A | 1 |
| Andreasen, N | 1 |
| Minthon, L | 1 |
| Blennow, K | 1 |
| Robert, P | 1 |
3 reviews available for tacrine and Disease Exacerbation
| Article | Year |
|---|---|
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; G | 2011 |
The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials.
Topics: Alzheimer Disease; Cognition; Disease Progression; Drug Therapy, Combination; Humans; Phosphatidylch | 1994 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therap | 2002 |
3 trials available for tacrine and Disease Exacerbation
| Article | Year |
|---|---|
Cholesterol and APOE genotype interact to influence Alzheimer disease progression.
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholesterol; Disease Progression; Dou | 2004 |
Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Disease Progression; Double-Blind Method; Humans; Lon | 1996 |
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; D | 2001 |
1 other study available for tacrine and Disease Exacerbation
| Article | Year |
|---|---|
Searching for drugs that combat Alzheimer's.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Antioxidants; Cholinesterase Inhibitors; Clinical Trial | 1996 |